Ankasa Regenerative Therapeutics focuses on developing advanced protein-based stem cell activation therapies to enhance tissue repair and regeneration. The company's lead product, ART352 L, aims to improve outcomes in spinal fusion surgeries by augmenting autografts used to treat degenerative changes in intervertebral discs. Preclinical data indicate that ART352 L significantly increases bone formation without causing unwanted bone overgrowth, thereby reducing the need for revision surgeries and associated complications. Ankasa's technology has potential applications in various bone reconstructive procedures, including dental and orthopedic implants, knee and hip replacements, fracture repair, and total joint arthroplasty revisions. The company operates in the regenerative medicine market, targeting healthcare providers and patients requiring advanced bone repair solutions. Ankasa generates revenue through venture investments and grants, having raised over $19 million from investors like Avalon Ventures, Heraeus Medical GmbH, Correlation Ventures, and Stanford University, along with over $6 million in grants from The California Institute of Regenerative Medicine (CIRM).

Keywords: regenerative medicine, stem cell activation, bone regeneration, spinal fusion, ART352 L, autograft augmentation, orthopedic implants, venture investment, tissue repair, Wnt proteins.